Generex Biotechnology Corp. (OTCMKTS:GNBT) is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.  Our company creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure.

The company goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering.  We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.

For more information please contact our Investor Relations:
Tel: 1-800-391-6755 Ext. 222
or email us at
investor@generex.com

 Generex Biotechnology Corp. is Traded on the OTC Markets our Trading Symbol is OTCQB:GNBT click the image above for our current stock price.

 Generex Biotechnology Corp. is SEC Reporting - Current and all our filings can be found on the SEC Edgar Database click on the image above for all our filings.

To read the transcript of the February 22, 2017 Generex Investor Call please click here.

To listen to the recording of the February 22, 2017 Generex Investor Call please click here.
Investor
​Relations
Generex
​Investor Call
Press Releases
  1. Generex Welcomes Dr. Yutaka Niihara, M.D., M.P.H. to Its Board of Directors
    January 25,2017
    MIRAMAR, Fla. & TORONTO--(BUSINESS WIRE)-- Generex Biotechnology Corporation (OTCPink:GNBT) is pleased to announce that Dr. Yutaka Niihara, M.D., M.P.H., Chairman & Chief Executive Officer of Emmaus Life Sciences, Inc. (www.emmauslifesciences.com), has joined the Generex Board of Directors as its Executive Chairman.
    READ MORE
  2. Generex Announces Deal to Acquire Controlling Equity Interest in Emmaus Life Sciences, Inc.
    January 23,2014
    MIRAMAR, Fla. & TORONTO--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCPink:GNBT) is pleased to announce that on January 16, 2017 it entered into a letter of intent (the “LOI”) for the acquisition of a controlling equity interest in Emmaus Life Sciences, Inc. (www.emmauslifesciences.com) (“Emmaus”). The Company filed a Form 8-K Current Report in respect of the LOI with the U.S. Securities and Exchange Commission (SEC) (www.sec.gov) on Friday, January 20, 2017. That 8-K provides comprehensive and detailed descriptions of the transaction terms.
    READ MORE
  3. Generex Announces Closing of Acquisition of Controlling Equity Interest in Hema Diagnostic Systems
    January 23,2014
    MIRAMAR, Florida & TORONTO, Canada, January 23, 2017 (BUSINESS WIRE) -- Generex Biotechnology Corporation (OTCPink:GNBT) is pleased to announce that on January 19, 2017 it consummated the previously announced acquisition of a controlling equity interest in Hema Diagnostic Systems, LLC (www.hemadiagnosticsystems.com) (“HDS”). The Company filed a Form 8-K Current Report in respect of the acquisition with the U.S. Securities and Exchange Commission (www.sec.gov) on Friday, January 20, 2017. That 8-K provides comprehensive and detailed descriptions of the transaction terms and the business of HDS. It also includes the audited financial statements of HDS.
    READ MORE
  4. Generex Announces Investor Conference Call
    January 28,2017
    MIRAMAR, Florida, January 30, 2017 (BUSINESS WIRE) -- Generex Biotechnology Corporation (OTCPink:GNBT) today announced that it will hold an investor conference call at 10 a.m. Eastern time on Wednesday, February 22, 2017. Dial-in instructions will be issued prior to the date of the call.
    READ MORE
  5. Generex Provides Update on Deal to Acquire Controlling Equity Interest in Emmaus Life Sciences, Inc.
    February 9, 2017
    MIRAMAR, Florida & TORONTO, Canada, February 9, 2017 (BUSINESS WIRE) – On January 23, 2017 Generex Biotechnology Corporation (OTCPink:GNBT) announced a letter of intent for the acquisition of a controlling equity interest in Emmaus Life Sciences, Inc. (www.emmauslifesciences.com) (“Emmaus”). The Company filed a Form 8-K Current Report in respect of the transaction with the U.S. Securities and Exchange Commission (SEC) (www.sec.gov) on January 20, 2017. That 8-K provides comprehensive and detailed descriptions of the transaction terms. Generex today announced that Emmaus has granted to Generex an extension of the payment date for an interim cash consideration payment in the amount of $1,500,000 to February 16, 2017.
    READ MORE
  6. Generex Announces Elimination of Outstanding Derivative Securities
    February 15, 2017
    MIRAMAR, Florida & TORONTO, Canada, February 15, 2017 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTCPink:GNBT) today announced that it has achieved the elimination of its outstanding derivative securities.
    READ MORE
  7. Generex Provides Access Information for Investor Conference Call Scheduled for February 22, 2017
    February 21, 2017
    MIRAMAR, Florida, February 21, 2017 (BUSINESS WIRE) -- Generex Biotechnology Corporation (OTCPink:GNBT) today announced the following access information for its investor conference call, to be hosted by Joseph Moscato, Company President & Chief Executive Officer, and his management team, tomorrow, Wednesday, February 22, 2017, at 10 am. Eastern time:
    READ MORE
  8. Generex Announces Reverse Stock Split
    March 14, 2017
    MIRAMAR, Florida & TORONTO, Canada, March 14, 2017 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTCPink:GNBT) today announced a reverse stock split of its shares of common stock at a ratio of 1-for-1000. As of the open of the market on March 14, 2017, the Company’s common stock will begin trading on a split-adjusted basis.
    READ MORE
  9. Generex Announces Featured Presentation of Cancer Immunotherapy Developed by Subsidiary at OPT Boston
    March 27, 2017
    MIRAMAR, FL--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTC Pink:GNBTD) today announced that Dr. Eric von Hofe, Ph.D., President of the Company’s wholly-owned immuno-therapeutics subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be a featured speaker at the Cambridge Healthtech Institute’s second annual Oligonucleotide & Peptide Therapeutics conference (OPT Boston) (www.optcongress.com) being held in Cambridge, MA March 27 – 29, 2017.
    READ MORE
  10. Generex Announces $115M Convertible Preferred Stock Financing; First Tranche Satisfies Emmaus Deposit
    March 29, 2017
    MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTC Pink:GNBTD) today announced that it has entered into a securities purchase agreement with an institutional investor pursuant to which such investor has agreed to purchase in a private placement (the “Private Placement”) in multiple tranches 109,000 shares of the Company’s newly designed Series H Convertible Preferred Stock (the “Series H CPS”) and 6,000 shares of the Company’s newly designed Series I Convertible Preferred Stock (the “Series I CPS”) (together, the “Preferred Stock”) for an aggregate purchase price of $115,000,000 ($1,000 per share of Preferred Stock). The Preferred Stock is convertible into shares of the Company’s common stock at a conversion price of $2.50 per share (subject to adjustment under certain circumstances).
    READ MORE
  11. Generex Announces Collaboration with Merck to Evaluate KEYTRUDA® (pembrolizumab) in Combination with AE37 in Patients with Triple-Negative Breast Cancer
    July 31, 2017
    July 31, 2017 09:30 AM Eastern Daylight Time MIRAMAR, FL‐‐(BUSINESS WIRE)‐‐Generex Biotechnology Corporation (www.generex.com) (OTCPink:GNBT) today announced that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com) has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada), through a wholly-owned subsidiary, to evaluate Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic triple-negative breast cancer. The study will evaluate preliminary safety and efficacy of the combination in a Phase II trial.
    READ MORE
  12. Generex Provides Summary of Ii-Key Hybrid Vaccine Platform
    August 7, 2017
    August 7, 2017 09:30 AM Eastern Daylight Time MIRAMAR, FL‐‐(BUSINESS WIRE)‐‐Generex Biotechnology Corporation (www.generex.com) (OTCPink:GNBT) today provided the following summary of the Ii-Key Hybrid Vaccine Platform under development by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). This summary has been prepared by Dr. Jason B. Terrell, MD, the Company’s Chief Medical and Scientific Officer, as a follow-up to last week’s announcement by Generex of a clinical trial collaboration agreement between Antigen Express and Merck (known as MSD outside the United States and Canada), through a wholly-owned subsidiary, to evaluate Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic triple-negative breast cancer.
    READ MORE
  13. Generex Announces Order for Hema Diagnostic Systems’ Rapid 1-2-3® Hema HIV EXPRESS® in Chile
    September 12, 2017
    HDS embarking on multiple-product commercialization efforts MIRAMAR, Florida, September 12, 2017 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTC Pink:GNBTD) (www.generex.com) today announced that its subsidiary, Hema Diagnostic Systems LLC (www.hemadiagnosticsystems.com), has received an initial order for its Rapid 1-2-3® Hema HIV EXPRESS® from Diagnostiko Ltda. (www.diagnostiko.cl) in Chile.
    READ MORE
  14. Generex Provides Summary of Ii-Key Hybrid Vaccine Platform Follow-Up to Antigen Express – Merck AE37 - KEYTRUDA® Collaboration
    September 20, 2017
    MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (www.generex.com) (OTCPink:GNBT) today provided the following summary of the Ii-Key Hybrid Vaccine Platform under development by its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). This summary has been prepared by Dr. Jason B. Terrell, MD, the Company’s Chief Medical and Scientific Officer, as a follow-up to last week’s announcement by Generex of a clinical trial collaboration agreement between Antigen Express and Merck (known as MSD outside the United States and Canada), through a wholly-owned subsidiary, to evaluate Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic triple-negative breast cancer.
    READ MORE
  15. Generex Announces Exclusive Distribution Contract For Rapid 1-2-3® Hema HIV EXPRESS® in Chile
    October 12, 2017
    MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCPink:GNBT) (www.generex.com) today announced that its subsidiary, Hema Diagnostic Systems, LLC (www.hemadiagnosticsystems.com), has entered into an exclusive contract with Imerlab Sociedad Comercial Limitada (www.imerlab.cl) for the distribution and sale of the Rapid 1-2-3® Hema HIV EXPRESS® diagnostic test in the Republic of Chile.
    READ MORE
  16. Generex Announces Results of Annual Stockholders’ Meeting
    November 27, 2017
    November 27, 2017 09:00 AM Eastern Standard Time MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCPink:GNBT) (www.generex.com) today announced the results of the annual meeting of the Company’s stockholders held on November 21, 2017.
    READ MORE
  17. Generex Announces Upgrade to OTCQB® Venture Market
    November 30, 2017
    November 30, 2017 - MIRAMAR, Fla. Generex Biotechnology Corporation (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (www.generex.com) today announced that trading in its common stock will be upgraded to the OTCQB® Venture Market on November 30, 2017 after a successful application to up-list from the OTC Pink Market.
    READ MORE
  18. Generex Announces Collaboration with Shenzhen BioScien Pharmaceuticals to Develop and Commercialize the AE37 Immunotherapeutic Vaccine for the Treatment of Prostate Cancer in China
    December 7, 2017
    MIRAMAR, Florida, December 7, 2017 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) (www.generex.com) today announced that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), has entered into a License and Research Agreement with Shenzhen BioScien Pharmaceuticals Co. Ltd. www.BioScien.cn to develop and commercialize the Antigen Express AE37 immunotherapeutic vaccine for prostate cancer in the People’s Republic of China (including Taiwan, Hong Kong, and Macau).
    READ MORE
For all Archived Press Releases please click here